Related Experiment Video
Updated: Jun 5, 2025
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
19.6K
Metformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study
Journal of Drugs in Dermatology : JDD
|December 4, 2024
Summary
Metformin may reduce the risk of non-melanoma skin cancers, including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). This protective effect was observed across various demographics, though not significantly in African American patients for SCC.
Area of Science:
- Dermatology
- Oncology
- Pharmacology
Background:
- Existing literature suggests metformin may offer protection against non-melanoma skin cancers.
- Non-melanoma skin cancers pose a significant health burden.
- Metformin is a widely available and generally well-tolerated medication.
Purpose of the Study:
- To evaluate metformin's potential in lowering the risk of non-melanoma skin cancers.
- Specifically investigating the impact on squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).
- Utilizing the All of Us research database for comprehensive analysis.
Main Methods:
- Retrospective case-control analysis of the All of Us database.
- Propensity score matching and multivariable regression analyses were employed.
- Controlled for confounding variables to assess metformin's impact on SCC and BCC incidence.
Main Results:
- Metformin exposure was associated with a reduced risk of non-melanoma skin cancer (SCC and BCC).
- Metformin decreased BCC risk across all sex and ethnicity groups.
- Metformin use was linked to lower SCC risk, except in African American patients.
Conclusions:
- Findings suggest a potential protective role for metformin against skin cancer, especially in individuals with skin of color.
- Further prospective research is needed to confirm metformin's efficacy in skin cancer chemoprevention for these populations.
More Related Videos
12:37Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
18.1K
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
04:12Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
14.2K
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
01:30Skin Cancer
3.4K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.4K
01:06Oral Hypoglycemic Agents: Glinides
139
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
139
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
02:59Cancer Prevention
6.1K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.1K